Mesoblast (ASX:MSB) has welcomed new research showing that its allogeneic cell therapy remestemcel-L delivers superior clinical outcomes compared with ruxolitinib for patients with steroid-refractory acute graft versus host disease. …
New analysis finds Mesoblast’s Remestemcel-L outperforms ruxolitinib in severe GvHD
December 14, 2025 Australian Biotech
Latest Video
New Stories
-
GBMA White Paper calls for reforms to strengthen supply chain resilience
August 10, 2026 - - Latest News -
France the first to provide comprehensive reimbursement for GLP-1s for weight loss while Australia looks on
August 10, 2026 - -
New Zealand's ACT announces plan for pharmacies to do a lot more, but also ownership and location reform
August 10, 2026 - -
Achieving value is meaningless if it undermines access to medicines
August 10, 2026 - -
Australia’s 'Biggest Week in Biotech' brings global life sciences leaders to the Gold Coast
August 9, 2026 - - Australian Biotech -
The 'Dispatched' Podcast - Week in review
August 7, 2026 - - Podcast -
A new generation is rewriting their lives living with Cystic Fibrosis
August 7, 2026 - - Latest News